Strategic partnerships Target collaborations with national cancer institutes and Alzheimer's research programs that have previously funded lung cancer and Alzheimer’s diagnostics to accelerate ICAP adoption and validation.

Early-stage partnerships Leverage the small team size to pursue pilot deployments with select biotech, CROs, and academic medical centers for proof-of-concept studies that demonstrate ICAP’s ability to detect low-abundance biomarkers.

Analytics and AI leverage Position the machine learning component as a differentiator by offering end-to-end data pipelines and regulatory-ready analytics to translate cell-response data into actionable disease state predictions for customers.

Funding alignment Identify grant-ready opportunities and government funding streams aligned with non-invasive diagnostics and cancer screening to extend runway and fund joint development with potential customers.

Market expansion Highlight potential for pan-cancer iCAP panels and lung cancer and Alzheimer’s screening to attract larger healthcare buyers and diagnostic distributors seeking diversified, non-invasive test portfolios.